Aeddula, Narothama ReddyPathireddy, SamataAnsari, AsifJuran, Peter J.2019-07-022019-07-022018-11-08Aeddula, N. R., Pathireddy, S., Ansari, A., & Juran, P. J. (2018). Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. BMJ case reports, 2018, bcr2018227161. doi:10.1136/bcr-2018-227161https://hdl.handle.net/1805/19817Hydralazine, a vasodilator, is commonly used as an adjunctive treatment for moderate to severe hypertension, heart failure and hypertensive emergencies in pregnancy. Hydralazine-induced lupus was first described in 1953. Clinical presentation ranges from arthralgia, myalgia, petechiae, or rash to single or multiorgan involvement. An occurrence of systemic vasculitis is a rare complication. When presented as the pulmonary-renal syndrome, it could have a rapidly progressive course which can be fatal. Here, we describe a case of hydralazine-associated rapidly progressive glomerulonephritis and pulmonary haemorrhage. We use this case to review the current literature and discuss and highlight the importance of a high degree of clinical acumen, early diagnosis and prompt treatment for better clinical outcomes.en-USAttribution-NonCommercial-NoDerivs 3.0 United StatesDrug interactionsRenal systemAcute renal failureVasculitisArticle